Articaine vs Dexmedetomidine Supplemented Articaine

Articaine and Dexmedetomidine - Supplemented Articaine for Arteriovenous Fistula Creation Under Ultrasound- Guided Supraclavicular Block

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04171349

Enrollment

Registered

2019-11-20

Start date

2019-06-01

Completion date

2019-11-01

Last updated

2019-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Failure

Keywords

Hemodialysis

Brief summary

The aim of this study to test efficacy of adding dexmedetomidine to articaine on sensory, motor and duration of analgesia during hemodialysis fistula creation under ultrasound guided supraclavicular block

Detailed description

Adult fifty patient with chronic renal failure on hemodialysis, scheduled for arteriovenous fistula creation under ultrasound guided supraclavicular block. Patients were randomly allocated in two group. The articaine group (group A) received 40 ml articaine hydrochloride 2% and articaine-dexmedetomidine group (group AD) received 40 ml. Of articaine 2% mixed with dexmedetomidine (1micogram/kg)

Interventions

DRUGArticaine

Vial

DRUGDexmedetomidine

Vial

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

25 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* adult patient with chronic renal failure on hemodialysis scheduled for radiocephalic fistula creation

Exclusion criteria

* Allergy to local anesthetics. * Infection at the site of needle insertion. * Those having international normalized ratio more than 1.5. * Coagulopathy. * Neuromuscular, or severe hepatic or severe pulmonary disease. * Those having epilepsy. * Patients who refused to participate.

Design outcomes

Primary

Measure	Time frame	Description
Duration of motor block	24 hours	Motor block time tested by Bromage scale measured in minutes
Duration of sensory block	24 hours	Sensory block time tested by pinprick test measured in minute

Secondary

Measure	Time frame	Description
Duration of analgesia	24 hours	Measured by visual analog scale score 4

Other

Measure	Time frame	Description
Sedation	24 hours	Measured by Ramsay sedation scale score 3

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026